<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656119</url>
  </required_header>
  <id_info>
    <org_study_id>2020-K-508</org_study_id>
    <nct_id>NCT04656119</nct_id>
  </id_info>
  <brief_title>Discovery of Biomarkers Related to the Efficacy and Adverse Reactions of Immune Checkpoint Inhibitors Based on Metabolism-genomics</brief_title>
  <official_title>Discovery of Biomarkers Related to the Efficacy and Adverse Reactions of Immune Checkpoint Inhibitors Based on Metabolism-genomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune checkpoint inhibitors (ICIs) are an important breakthrough in cancer therapy and have&#xD;
      been increasingly used.However, ICIs can cause a unique spectrum of side effects termed&#xD;
      immune-related adverse events (irAEs),which can affect any organ systems and in some cases&#xD;
      are fulminant or even fatal.In clinical practice, irAEs and clinical efficacy maybe various&#xD;
      for patients with same standard treatment, and some studies have shown that gene and&#xD;
      metabolic differences in cancer patients may be an important factor. In this project,&#xD;
      peripheral blood samples from cancer patients will be collected prospectively at baseline,&#xD;
      and at regular intervals (2 cycles, about 6 weeks) for about 30 weeks, then these blood&#xD;
      samples will be analyzed using the technique of genomics, metabonomics.&#xD;
&#xD;
      The investigators aim to find biomarkers associated with irAE or clinical efficacy. When the&#xD;
      sample size and data is big enough, the investigators plan to establish a prediction model&#xD;
      using machine learning to access the safety and efficacy of ICIs for cancer patients. Our&#xD;
      study have important clinical implications in the prediction and early management of severe,&#xD;
      potentially life-threatening immune-related toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">November 3, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>immune-related adverse events incidence</measure>
    <time_frame>November,2020-November,2025</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>November,2020-November,2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial response (PR)</measure>
    <time_frame>November,2020-November,2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stable disease (SD)</measure>
    <time_frame>November,2020-November,2025</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive disease (PD)</measure>
    <time_frame>November,2020-November,2025</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>patients without irAEs or patients with good efficacy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with irAEs or patients with poor efficacy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>there is no intervention in our study</intervention_name>
    <description>there is no intervention in our study</description>
    <arm_group_label>patients with irAEs or patients with poor efficacy</arm_group_label>
    <arm_group_label>patients without irAEs or patients with good efficacy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        the participants make up the study population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignant tumor, no relative contraindications for&#xD;
             immunotherapy, in line with the standards of immunotherapy&#xD;
&#xD;
          -  Receive immune checkpoint inhibitors (ICIs) for the first time or have received ICIs&#xD;
             but no immune-related adverse reactions have occurred&#xD;
&#xD;
          -  Have provided informed consent, are willing to participate in study and routine&#xD;
             follow-up&#xD;
&#xD;
          -  At least one measurable lesion according to Guidelines for response criteria for use&#xD;
             in trials testing immunotherapeutics (iRECIST)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active, known, suspected or a documented history of autoimmune disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG) performance status 3-4&#xD;
&#xD;
          -  Long-term hormone therapy，corticosteroids (&gt;10mg/day prednisone curative dose)&#xD;
&#xD;
          -  Subjects with human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Subjects with other tumors&#xD;
&#xD;
          -  Myocardial infarction, poorly control led arrhythmia, New York Heart Association&#xD;
             (NYHA) standard III-IV cardiac insufficiency or left ventricular ejection fraction&#xD;
             (LVEF)&lt;50% in the last 6 month&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Active or a documented history of interstitial pneumonia, pneumoconiosis, radiation&#xD;
             pneumonia, drug-related pneumonia, severely impaired lung function&#xD;
&#xD;
          -  Common Terminology Criteria for Adverse Events (CTCAE) peripheral neuropathy grade≥2&#xD;
&#xD;
          -  History of alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenchao Lu, Master</last_name>
    <phone>18811183790</phone>
    <email>wenchaolu621@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhixia Zhao, Master</last_name>
    <phone>010-85231786</phone>
    <email>zhixia.1002@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chao-yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lu Wenchao, Master</last_name>
      <phone>18811183790</phone>
      <email>wenchaolu621@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Lihong Liu</investigator_full_name>
    <investigator_title>Director of Pharmacy department</investigator_title>
  </responsible_party>
  <keyword>Immune checkpoint inhibitors</keyword>
  <keyword>Immune-related adverse events</keyword>
  <keyword>Genomics</keyword>
  <keyword>Metabonomics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

